Trade Landos Biopharma, Inc. - LABP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 21.95 |
| Open | 21.85 |
| 1-Year Change | 5650% |
| Day's Range | 21.85 - 22.11 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 21.95 | 0.09 | 0.41% | 21.86 | 22.10 | 21.85 |
| Apr 22, 2024 | 21.82 | 0.25 | 1.16% | 21.57 | 22.01 | 21.55 |
| Apr 19, 2024 | 21.68 | 0.08 | 0.37% | 21.60 | 21.75 | 21.46 |
| Apr 18, 2024 | 21.66 | 0.20 | 0.93% | 21.46 | 21.70 | 21.46 |
| Apr 17, 2024 | 21.63 | 0.22 | 1.03% | 21.41 | 21.63 | 21.40 |
| Apr 16, 2024 | 21.45 | 0.00 | 0.00% | 21.45 | 21.47 | 21.37 |
| Apr 15, 2024 | 21.45 | 0.00 | 0.00% | 21.45 | 21.49 | 21.37 |
| Apr 12, 2024 | 21.45 | 0.00 | 0.00% | 21.45 | 21.46 | 21.41 |
| Apr 11, 2024 | 21.45 | -0.01 | -0.05% | 21.46 | 21.47 | 21.41 |
| Apr 10, 2024 | 21.46 | 0.05 | 0.23% | 21.41 | 21.47 | 21.41 |
| Apr 9, 2024 | 21.47 | 0.06 | 0.28% | 21.41 | 21.47 | 21.41 |
| Apr 8, 2024 | 21.45 | -0.10 | -0.46% | 21.55 | 21.63 | 21.42 |
| Apr 5, 2024 | 21.45 | 0.04 | 0.19% | 21.41 | 21.55 | 21.41 |
| Apr 4, 2024 | 21.45 | 0.05 | 0.23% | 21.40 | 21.50 | 21.40 |
| Apr 3, 2024 | 21.40 | 0.03 | 0.14% | 21.37 | 21.55 | 21.37 |
| Apr 2, 2024 | 21.43 | 0.06 | 0.28% | 21.37 | 21.45 | 21.36 |
| Apr 1, 2024 | 21.45 | 0.08 | 0.37% | 21.37 | 21.65 | 21.37 |
| Mar 28, 2024 | 21.40 | 0.05 | 0.23% | 21.35 | 21.89 | 21.30 |
| Mar 27, 2024 | 21.30 | 0.00 | 0.00% | 21.30 | 21.54 | 21.30 |
| Mar 26, 2024 | 21.35 | -0.15 | -0.70% | 21.50 | 21.58 | 21.30 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Landos Biopharma, Inc. Company profile
About Landos Biopharma Inc
Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.
| Industry: | Biotechnology & Medical Research (NEC) |
1800 Kraft Drive, Suite 216
24060
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com